(Total Views: 654)
Posted On: 08/11/2020 10:40:25 AM
Post# of 153963
Hard to rate. I think the results are very promising. The only real downside is the expectations of us investors.
We need to get more color in terms of the data, but I suspect this is going to be very good. Easily the best treatment available.
I also suspect that as we get more data and results from Severe critical trial, as well as data on thousands of patients (EUA or phase 4) it will become clear just how well this works.
But back to this data. If all we are able to infer from this data is that we speed recovery over SOC it's a win. But I suspect there will be more benefit.
So, I'll temper myself and say this is an 8
We need to get more color in terms of the data, but I suspect this is going to be very good. Easily the best treatment available.
I also suspect that as we get more data and results from Severe critical trial, as well as data on thousands of patients (EUA or phase 4) it will become clear just how well this works.
But back to this data. If all we are able to infer from this data is that we speed recovery over SOC it's a win. But I suspect there will be more benefit.
So, I'll temper myself and say this is an 8
(4)
(0)
